文献速递心脏核医学肿瘤 PET/CT

18F-FMISO PET/CT检测结节病心脏及心外受累缺氧病灶

18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis.
PubMed 文献 · J Nucl Cardiol · 2019-12-09

前瞻性纳入10例疑似心脏受累的结节病患者,分别行18F-FMISO与18F-FDG PET/CT。9例心肌局灶FDG摄取确诊心脏结节病,FMISO在7例心脏病灶(77.8%)和6例心外病灶(54.5%)显示摄取,且FMISO阳性病灶SUVmax与代谢体积均高于阴性病灶。FMISO无心肌生理性摄取且无需特殊准备,有望检测结节病缺氧病灶。

要点

  • FMISO在结节病患者中无心肌生理性摄取,无需特殊饮食准备。
  • FMISO可检测心脏(77.8%)及心外(54.5%)结节病病灶的缺氧。
  • FMISO阳性病灶SUVmax和代谢体积均高于FMISO阴性病灶。

核心结论

  • FMISO无心肌生理性摄取且无需特殊准备,PET有潜力检测结节病患者的缺氧病灶。

研究设计与样本

  • 前瞻性纳入10例连续疑似心脏受累的结节病患者,行FMISO与FDG PET/CT并视觉与半定量评估摄取。

主要发现

  • 9例心肌局灶FDG摄取者诊断为心脏结节病。
  • 心外病灶中FDG摄取见于8个淋巴结和3个肺病灶。
  • FMISO摄取见于7个心脏病灶(77.8%)和6个心外病灶(54.5%)。
  • FMISO阳性病灶SUVmax高于阴性病灶:心脏9.9(IQR 8.4-10.0)vs 7.3(IQR 6.3-8.2);非心脏17.6(IQR 14.5-19.3)vs 6.1(IQR 5.9-6.2),P=0.006。
  • FMISO阳性病灶代谢体积显著高于阴性病灶:111.3(IQR 78.3-135.7)vs 6.4(IQR 1.9-23.3),P=0.0009。

关键数值与推荐

  • FDG代谢体积以血池平均SUV×1.5为阈值界定边界计算。
  • FMISO与FDG摄取均以最大标准化摄取值(SUVmax)半定量评估。

临床怎么用

  • 对疑似心脏结节病患者,FMISO PET/CT无需特殊饮食准备且无心肌生理性摄取,可作为检测缺氧病灶的补充手段。

局限性

  • 样本量仅10例,结论需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 18F-fluoromisonidazole (FMISO) is a hypoxia positron emission tomography (PET) tracer. Here, we evaluated cardiac and extra-cardiac sarcoidosis using both FMISO and 18F-fluorodeoxyglucose (FDG) PET/CT in a prospective cohort of patients with sarcoidosis. METHODS: Ten consecutive sarcoidosis patients with suspected cardiac involvement were prospectively enrolled. Each patient fasted overnight (for ≥ 18 hours) preceded by a low-carbohydrate diet before FDG PET/CT but not given special dietary instructions before the FMISO PET/CT scan. We visually and semiquantitatively assessed the uptakes of FMISO and FDG using the maximal standardized uptake value (SUVmax). The metabolic volume (MV) of FDG was calculated as the volume within the boundary determined by the threshold (mean SUV of blood pool × 1.5). RESULTS: Nine patients showed focal FDG uptake in the myocardium and were diagnosed with cardiac sarcoidosis. Among the patients with extra-cardiac lesions, FDG uptake was seen in 8 lymph nodes and 3 lung lesions. FMISO uptake was seen in the 7 cardiac (77.8%) and 6 extra-cardiac (54.5%) lesions. None of the patients showed physiological FMISO uptake in the myocardium. The SUVmax values of the lesions with FMISO uptake were higher than those of the lesions without FMISO uptake in both the cardiac (SUVmax: 9.9, IQR: 8.4-10.0 vs 7.3, IQR: 6.3-8.2) and non-cardiac lesions (SUVmax: 17.6, IQR: 14.5-19.3 vs 6.1, IQR: 5.9-6.2; P = 0.006). The MV values of the lesions with FMISO uptake were significantly higher than those of the lesions without FMISO uptake (111.3, IQR: 78.3-135.7 vs 6.4, IQR: 1.9-23.3; P = 0.0009). CONCLUSIONS: FMISO showed no physiological myocardial uptake and did not require special preparation. FMISO PET has the potential to detect hypoxic lesions in patients with sarcoidosis.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Furuya S, Naya M, Manabe O, et al. 18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. J Nucl Cardiol. 2019. PMID: 31820409. doi:10.1007/s12350-019-01976-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。